Yttrium Y-90 clivatuzumab tetraxetan
- Generic Name
- Yttrium Y-90 clivatuzumab tetraxetan
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 943976-23-6
- Unique Ingredient Identifier
- 2L271110ED
- Background
Yttrium Y-90 clivatuzumab tetraxetan is under investigation in clinical trial NCT00603863 (Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2012-01-16
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT01510561
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of North Carolina Medical Center, Chapel Hill, North Carolina, United States
🇺🇸Goshen Center for Cancer Care, Goshen, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath